(European Union’s Horizon 2020 Research and Innovation (101007931))
(K139105)
(2020-4.1.1.-TKP2020)
(2020-1.1.5-GYORSÍTÓSÁV-2021-00011)
Subjects:
Biochemistry and molecular biology
Chemical sciences
Patients diagnosed with metastatic uveal melanoma (MUM) have a poor survival prognosis.
Unfortunately for this rare disease, there is no known cure and suitable therapeutic
options are limited. HDAC6 inhibitors (HDAC6i) are currently in clinical trials for
other cancers and show potential beneficial effects against tumor cell survival in
vitro and in vivo. In MUM cells, HDAC6i show an anti-proliferative effect in vitro
and in preclinical xenograft models. The use of HDAC6 inhibitors as a treatment option
for MUM should be explored further. Therefore, this review discusses (1) what is known
about HDAC6i in MUM and (2) whether HDAC6 inhibitors offer a potential therapeutic
option for MUM.
